Acomhal Research has received a significant boost from America’s Seed Fund through the National Institutes of Health’s Small Business Technology Transfer (STTR) program. This grant provides Acomhal with up to $225,000 for the early-stage development of a biodegradable nano-capsule designed to deliver a biological product capable of eradicating glioblastoma cells.

“Of all the discoveries in academia, only relatively few are developed commercially because of the time required and the different skills needed to bring an idea to the clinic. It takes an entrepreneurial strategy or a commercial partner within a supportive, innovative environment for the idea to reach the marketplace,” said Samy Lamouille, co-founder and chief executive officer of Acomhal Research. “We have started our company and successfully competed for funding to hopefully move into phase 1 clinical trials and develop our product to attract investors. The reward will be to see our novel approach implemented therapeutically, where it will help people live longer and maintain a higher quality of life.”

Acomhal was selected out of nearly 100 applicants from 40 institutions.